FDA accepts Teva's resubmission of SD-809 NDA

21 October 2016
teva-logo-big

The US Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD).

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 3, 2017, said Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA), which is developing the compound.

Back in June, the FDA issued a complete response letter regarding the NDA, asking Teva to examine blood levels of certain metabolites. SD-809 became part of Teva’s central nervous system product portfolio with the $3.2 billion acquisition of Auspex Pharmaceuticals, completed in May 2015.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical